The Week Ahead: Hom...
Services: Diversified Services
Genetic Technologies Limited (GENE: NASDAQ)
$2.85 0.17 | 6.34%
05/17/13 - 04:00 PM ET
Ratio Comparisons
| Company | Industry | S&P 500 | |
| Valuation Ratios | |||
|---|---|---|---|
| P/E Ratio (TTM) | n.a. | 22.50 | 17.70 |
| P/E High - Last 5 Yrs | n.a. | 86.70 | 67.70 |
| P/E Low - Last 5 Yrs | n.a. | 10.60 | 12.50 |
| Beta | 1.27 | 1.02 | 0.98 |
| Price to Sales (TTM) | 3.80 | 3.78 | 1.42 |
| Price to Book (MRQ) | 3.93 | 4.26 | 2.41 |
| Price to Tangible Book (MRQ) | 4.50 | 43.64 | 5.08 |
| Price to Cash Flow (TTM) | 76.70 | 14.60 | 9.80 |
| Price to Free Cash Flow (TTM) | -5.90 | 176.50 | 17.40 |
| Dividends | |||
| Dividend Yield (%) | 0.00 | 1.80 | 2.10 |
| Dividend Yield - 5 Yr Avg (%) | n.a. | 1.80 | 2.30 |
| Dividend 5 Yr Growth Rate (%) | n.a. | 92.12 | 2.80 |
| Payout Ratio (TTM) | 0.00 | 92.00 | 37.00 |
| Sales (MRQ) vs Qtr 1 Yr Ago (%) | n.a. | -4.80 | 0.30 |
| Sales (TTM) vs TTM 1 Yr Ago (%) | -40.60 | -14.70 | 2.20 |
| Growth Rates (%) | |||
| Sales - 5 Yr Growth Rate (%) | 1.87 | 3.38 | 3.62 |
| EPS (MRQ) vs Qtr 1 Yr Ago (%) | n.a. | 305.30 | 99.90 |
| EPS (TTM) vs TTM 1 Yr Ago (%) | n.a. | 305.30 | 99.90 |
| EPS - 5 Yr Growth Rate (%) | n.a. | 19.77 | 8.12 |
| Capital Spending - 5 Yr Growth Rate (%) | n.a. | 3.15 | 3.83 |
| Financial Strength | |||
| Quick Ratio (MRQ) | n.a. | 1.50 | 1.10 |
| Current Ratio (MRQ) | n.a. | 1.70 | 1.60 |
| LT Debt to Equity (MRQ) | 0.00 | 0.25 | 0.73 |
| Total Debt to Equity (MRQ) | n.a. | 0.29 | 0.86 |
| Interest Coverage (TTM) | n.a. | 17.10 | 6.70 |
| Profitability Ratios (%) | |||
| Gross Margin (TTM) | n.a. | 71.30 | 47.80 |
| Gross Margin - 5 Yr Avg | 87.60 | 64.60 | 47.00 |
| EBITD Margin (TTM) | n.a. | 29.20 | 19.50 |
| EBITD - 5 Yr Avg | -21.32 | 0.00 | 0.00 |
| Pre-Tax Margin (TTM) | n.a. | 21.80 | 11.70 |
| Pre-Tax Margin - 5 Yr Avg | -37.70 | 15.40 | 10.20 |
| Management Effectiveness (%) | |||
| Net Profit Margin (TTM) | 0.00 | 0.15 | 0.09 |
| Net Profit Margin - 5 Yr Avg | -8.20 | 9.60 | 6.30 |
| Return on Assets (TTM) | 0.00 | 10.50 | 3.20 |
| Return on Assets - 5 Yr Avg | -7.40 | 6.30 | 2.30 |
| Return on Investment (TTM) | n.a. | 17.70 | 8.50 |
| Return on Investment - 5 Yr Avg | -9.10 | 10.40 | 5.90 |
| Efficiency | |||
| Revenue/Employee (TTM) | 181,313.00 | n.a. | n.a. |
| Net Income/Employee (TTM) | 0.00 | n.a. | n.a. |
| Receivable Turnover (TTM) | n.a. | 5.10 | 7.90 |
| Inventory Turnover (TTM) | n.a. | 5.80 | 7.70 |
| Asset Turnover (TTM) | 0.00 | 0.60 | 0.40 |
Portfolios with GENE
- Portfolio NameUser Type
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- Contributor14 Penny Stocks Get Delisti...
- UserExperimental Equities
- UserMBW
- Userann's prorfolio
Latest GENE Headlines from TheStreet
- STUDY VALIDATES BREVAGen MORE ACCURATELY IDENTIFIES BREAST CANCER RISK LEADING TO INCREASED BREAST HEALTH COMPLIANCE 04.15.13 | 12:04 pm
- The Centers For Women's Health In Stamford CT Pioneers Breast Cancer Risk Assessment 03.18.13 | 12:03 pm
- 5 Stocks Ready to Break Out 02.22.13 | 12:02 pm
- 4 Stocks Under $10 Making Big Moves 10.19.12 | 02:10 pm
- 4 Biotech Stocks Under $10 Soaring Higher 09.25.12 | 02:09 pm
- 8 Stocks Under $10 Ripping Higher 01.26.12 | 02:01 pm
- Optimer Soars on Antibiotic Data 11.11.08 | 12:11 pm
- Biotech Buzz: Big Strides in Alzheimer's Drugs
01.10.08 | 05:01 pm - Funny Money 12.10.07 | 01:12 pm
- Ties May Bind Apple's CEO to Board 09.06.06 | 04:09 pm
Press Releases for GENE
- BREVAGen Reclassified 64% Of Intermediate Gail Risk Subjects(1) (Graphic: Business Wire) - Business Wire 04.10.12 | 09:04 am
- Break-Through Invention For Treating Cancer - Business Wire 11.07.11 | 10:11 am
- Genetic Technologies Limited Announces Quarterly Activities Report For The Quarter Ended 30 September 2011 - Business Wire 10.26.11 | 11:10 am
- Genetic Technologies’ BREVAGen™ Changing The Way US Physicians Assess Breast Cancer Risk - Business Wire 10.18.11 | 09:10 am
- Genetic Technologies Limited Appoints Dr. Mervyn Cass As Company Director - Business Wire 10.03.11 | 10:10 am
Partner Headlines for GENE
- Morning Market Losers - Benzinga 11.28.12 | 09:11 am
- Genetic Technologies Executes Covenant Not to Sue And Release Agreement with One Lambda - Benzinga 10.18.12 | 01:10 pm
- 3 Best Biotech Stocks For This Week (Part VI) - Seeking Alpha 10.16.12 | 08:10 am
- Morning Market Movers - Benzinga 09.25.12 | 09:09 am
- Genetic Technologies Moving On News This Morning - Seeking Alpha 08.08.12 | 09:08 am
- Healthcare Business Recap: Merck's Potential AIDS CURE, Genetic Tech SPIKES - Wall St. Cheat Sheet 07.27.12 | 08:07 am
- Genetic Technologies Executes Exclusive Distribution Agreement with Rosetta Genomics - Benzinga 06.01.12 | 01:06 pm
- Netflix, Take-Two Among Stocks Attracting Investors and Traders Now - Wall St. Cheat Sheet 05.23.12 | 02:05 am
- Afternoon Market Top Percentage Gainers and Losers (CAAS, GENE, HNSN, SYMX, TPX, SCOK, QXM, IDIX, AIB, HERO) - Benzinga 04.08.11 | 01:04 pm
